Is orphan drug pricing blowing a bubble? The unique situation of orphan drugs and why high prices will likely persistdoi:10.1517/21678707.2013.829401John-Paul MichaudRobin ModiM Ian PhillipsTaylor & Francis
These cakes were exclusive to the wealthy, as sugar was not readily available and very expensive.With the advent of the Industrial Revolution, sugar was more affordable and cakes were seen at all levels of income. During the 1700s candles were added to the cakes. The candles totaled the...
Even if the painstaking process of target discovery and drug discovery yields an Investigational New Drug (IND), subsequent success rates in the clinic remain low. Historically, almost 90% of all compounds that enter clinical trials fail to gain approval, and this increases to 94% for orphan d...
Jesus meets us women today, just as He met Mary Magdalene when she was weeping at His tomb on the resurrection morning. He asks us the same question too: "Woman, why are you weeping". "He knows every detail of what is happening to us" (Job 23:10 – Living). He is not ignorant....
Newer orphan drugs are generally sold at high prices, which has raised the question about the sustainability of the orphan drug market and the possibility of a bubble. As more orphan drugs enter the market, reimbursement policies from payers could shift away from full reimbursement. But the ...
Hence, it was tempting to generalize these observations: agonists were natural and antagonists were synthetic and without defined structural limits. Therefore, antagonists were considered the only drug candidates (or tools for pharmacological and physiological investigations) until synthetic agonists and ...